Sofosbuvir‐based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series

Abstract

Full dose sofosbuvir/simeprevir or sofosbuvir/ledipasvir therapy for HCV-infected patients with end stage renal disease was well tolerated with no discontinuation owing to side effects and no significant adverse events.